Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer.

Du L, Rao G, Wang H, Li B, Tian W, Cui J, He L, Laffin B, Tian X, Hao C, Liu H, Sun X, Zhu Y, Tang DG, Mehrpour M, Lu Y, Chen Q.

Cancer Res. 2013 Apr 15;73(8):2682-94. doi: 10.1158/0008-5472.CAN-12-3759. Epub 2013 Feb 15.

2.

Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis.

Wang Q, Qian J, Wang F, Ma Z.

Oncol Rep. 2012 Dec;28(6):2029-34. doi: 10.3892/or.2012.2025. Epub 2012 Sep 12.

PMID:
22972305
3.

CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.

Cheng Y, Tao L, Xu J, Li Q, Yu J, Jin Y, Chen Q, Xu Z, Zou Q, Liu X.

Mol Carcinog. 2014 Sep;53(9):686-97. doi: 10.1002/mc.22021. Epub 2013 May 16.

PMID:
23681900
4.

Enrichment of colorectal cancer stem cells through epithelial-mesenchymal transition via CDH1 knockdown.

Ye J, Wu D, Shen J, Wu P, Ni C, Chen J, Zhao J, Zhang T, Wang X, Huang J.

Mol Med Rep. 2012 Sep;6(3):507-12. doi: 10.3892/mmr.2012.938. Epub 2012 Jun 7.

PMID:
22684815
5.

Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.

Geng S, Guo Y, Wang Q, Li L, Wang J.

Arch Dermatol Res. 2013 Jan;305(1):35-47. doi: 10.1007/s00403-012-1260-2. Epub 2012 Jun 28.

PMID:
22740085
6.

Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX.

Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR.

PLoS One. 2012;7(10):e46514. doi: 10.1371/journal.pone.0046514. Epub 2012 Oct 19.

7.

Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.

Reeder JA, Gotley DC, Walsh MD, Fawcett J, Antalis TM.

Cancer Res. 1998 Aug 15;58(16):3719-26.

8.

Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.

Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM.

Cancer Med. 2012 Aug;1(1):5-16. doi: 10.1002/cam4.4. Epub 2012 Jun 8.

9.

Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.

Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X, Wu C.

Mol Cell Biochem. 2012 Apr;363(1-2):427-36. doi: 10.1007/s11010-011-1195-5. Epub 2011 Dec 21.

PMID:
22187223
10.

Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production.

Hiraga T, Ito S, Nakamura H.

Cancer Res. 2013 Jul 1;73(13):4112-22. doi: 10.1158/0008-5472.CAN-12-3801. Epub 2013 Apr 30.

11.

Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs.

Rao GH, Liu HM, Li BW, Hao JJ, Yang YL, Wang MR, Wang XH, Wang J, Jin HJ, Du L, Chen Q.

Acta Pharmacol Sin. 2013 Jun;34(6):793-804. doi: 10.1038/aps.2013.56.

12.

L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers.

Gavert N, Vivanti A, Hazin J, Brabletz T, Ben-Ze'ev A.

Mol Cancer Res. 2011 Jan;9(1):14-24. doi: 10.1158/1541-7786.MCR-10-0406. Epub 2010 Dec 1.

13.

Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.

Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM.

Anticancer Drugs. 2010 Nov;21(10):897-906. doi: 10.1097/CAD.0b013e32833f2f77.

PMID:
20838207
14.

A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.

La Fleur L, Johansson AC, Roberg K.

PLoS One. 2012;7(9):e44071. doi: 10.1371/journal.pone.0044071. Epub 2012 Sep 25.

15.

Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.

Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Björkholm M, Jia J, Xu D.

Oncogene. 2013 Sep 5;32(36):4203-13. doi: 10.1038/onc.2012.441. Epub 2012 Oct 8.

PMID:
23045275
16.

Maintenance of the stemness in CD44(+) HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression.

Ju SY, Chiou SH, Su Y.

Stem Cell Res. 2014 Jan;12(1):86-100. doi: 10.1016/j.scr.2013.09.011. Epub 2013 Oct 2.

17.

BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells.

Sarkar D, Shields B, Davies ML, Müller J, Wakeman JA.

Int J Cancer. 2012 Jan 15;130(2):328-37. doi: 10.1002/ijc.26029. Epub 2011 May 28.

18.

Bone marrow-derived CD11b+Jagged2+ cells promote epithelial-to-mesenchymal transition and metastasization in colorectal cancer.

Caiado F, Carvalho T, Rosa I, Remédio L, Costa A, Matos J, Heissig B, Yagita H, Hattori K, da Silva JP, Fidalgo P, Pereira AD, Dias S.

Cancer Res. 2013 Jul 15;73(14):4233-46. doi: 10.1158/0008-5472.CAN-13-0085. Epub 2013 May 30.

19.

Cellular prion protein promotes glucose uptake through the Fyn-HIF-2α-Glut1 pathway to support colorectal cancer cell survival.

Li QQ, Sun YP, Ruan CP, Xu XY, Ge JH, He J, Xu ZD, Wang Q, Gao WC.

Cancer Sci. 2011 Feb;102(2):400-6. doi: 10.1111/j.1349-7006.2010.01811.x. Erratum in: Cancer Sci. 2012 Mar;103(3):606.

20.

A switch from CD44⁺ cell to EMT cell drives the metastasis of prostate cancer.

Shang Z, Cai Q, Zhang M, Zhu S, Ma Y, Sun L, Jiang N, Tian J, Niu X, Chen J, Sun Y, Niu Y.

Oncotarget. 2015 Jan 20;6(2):1202-16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk